3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Stomach Neoplasms
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Glioblastoma
1
Drug-Related Side Effects and Adverse Reactions
1
Depression
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anxiety Disorders
1
All Solid Tumors
1
Interventions
Gemcitabine
15
pembrolizumab
13
Doxorubicin
13
Radiotherapy
12
Docetaxel
9
Nivolumab
8
Filgrastim
7
Cyclophosphamide
7
pazopanib
6
Ifosfamide
6
130-nm albumin-bound paclitaxel
5
Temozolomide
4
Irinotecan
4
Ipilimumab
4
Imatinib Mesylate
4
Albumin-Bound Paclitaxel
4
talimogene laherparepvec
3
surufatinib
3
pegfilgrastim
3
eribulin
3
atezolizumab
3
Vinorelbine
3
Sirolimus
3
Peripheral Blood Stem Cell Transplantation
3
PM 01183
3
Drug Therapy
3
Cisplatin
3
toripalimab
2
spartalizumab
2
selinexor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Sarcoma
×
Pharmaceutical Preparations
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled